Dr. Dong Yu currently is Senior Vice President of Research at Dynavax Technologies.  Prior to joining Dynavax, Dr. Yu was the Head of Preclinical R&D US at GSK Vaccines. He received the PhD from University of Connecticut Health Center. He was a faculty member at Washington University in Saint Louis and the Head of Microbial Molecular Biology at Novartis Vaccines prior to joining GSK Vaccines in 2015.  Dr. Yu authored over 40 publications in various journals and books. His publications reflect his research interests in virology, infectious diseases, and vaccines. Dr. Benjamin Petsch, Senior Director Prophylactic Vaccine Research at CureVac AG, Benjamin Petsch joined CureVac in 2010 as a scientist in the vaccines department developing mRNA based vaccines against infectious diseases and is heading the department since 2013. He received his university degree from Ludwig-Maximilians-University of Munich and performed his doctoral thesis at the Friedrich-Loeffler-Institut, Tübingen, where he continued as a postdoc and research group leader working on mRNA vaccination against Influenza and on intervention of Influenza replication using small molecules. Dr. Petsch has a 10+ years scientific experience on mRNA based prophylactic vaccines.

• Preface.- mRNA-based vaccines and mode of action.- Self-Amplifying mRNA-Based Vaccine Technology and its Mode of Action.- Formulation and Delivery Technologies for mRNA Vaccines.- Messenger RNA-based vaccines against infectious diseases.- Emerge gate for Therapeutics applications of mRNA based drug.- Clinical Development of mRNA Vaccines: Challenges and Opportunities.- Regulatory Considerations on the Development of mRNA Vaccines.

Dr. Dong Yu currently is Senior Vice President of Research at Dynavax Technologies.  Prior to joining Dynavax, Dr. Yu was the Head of Preclinical R&D US at GSK Vaccines. He received the PhD from University of Connecticut Health Center. He was a faculty member at Washington University in Saint Louis and the Head of Microbial Molecular Biology at Novartis Vaccines prior to joining GSK Vaccines in 2015.  Dr. Yu authored over 40 publications in various journals and books. His publications reflect his research interests in virology, infectious diseases, and vaccines. Dr. Benjamin Petsch, Senior Director Prophylactic Vaccine Research at CureVac AG, Benjamin Petsch joined CureVac in 2010 as a scientist in the vaccines department developing mRNA based vaccines against infectious diseases and is heading the department since 2013. He received his university degree from Ludwig-Maximilians-University of Munich and performed his doctoral thesis at the Friedrich-Loeffler-Institut, Tübingen, where he continued as a postdoc and research group leader working on mRNA vaccination against Influenza and on intervention of Influenza replication using small molecules. Dr. Petsch has a 10+ years scientific experience on mRNA based prophylactic vaccines.

• Preface.- mRNA-based vaccines and mode of action.- Self-Amplifying mRNA-Based Vaccine Technology and its Mode of Action.- Formulation and Delivery Technologies for mRNA Vaccines.- Messenger RNA-based vaccines against infectious diseases.- Emerge gate for Therapeutics applications of mRNA based drug.- Clinical Development of mRNA Vaccines: Challenges and Opportunities.- Regulatory Considerations on the Development of mRNA Vaccines.

Dr. Dong Yu currently is Senior Vice President of Research at Dynavax Technologies.  Prior to joining Dynavax, Dr. Yu was the Head of Preclinical R&D US at GSK Vaccines. He received the PhD from University of Connecticut Health Center. He was a faculty member at Washington University in Saint Louis and the Head of Microbial Molecular Biology at Novartis Vaccines prior to joining GSK Vaccines in 2015.  Dr. Yu authored over 40 publications in various journals and books. His publications reflect his research interests in virology, infectious diseases, and vaccines. Dr. Benjamin Petsch, Senior Director Prophylactic Vaccine Research at CureVac AG, Benjamin Petsch joined CureVac in 2010 as a scientist in the vaccines department developing mRNA based vaccines against infectious diseases and is heading the department since 2013. He received his university degree from Ludwig-Maximilians-University of Munich and performed his doctoral thesis at the Friedrich-Loeffler-Institut, Tübingen, where he continued as a postdoc and research group leader working on mRNA vaccination against Influenza and on intervention of Influenza replication using small molecules. Dr. Petsch has a 10+ years scientific experience on mRNA based prophylactic vaccines.

• Preface.- mRNA-based vaccines and mode of action.- Self-Amplifying mRNA-Based Vaccine Technology and its Mode of Action.- Formulation and Delivery Technologies for mRNA Vaccines.- Messenger RNA-based vaccines against infectious diseases.- Emerge gate for Therapeutics applications of mRNA based drug.- Clinical Development of mRNA Vaccines: Challenges and Opportunities.- Regulatory Considerations on the Development of mRNA Vaccines.